| 1.995 0.165 (9.02%) | 10-09 15:47 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.37  |
1-year : | 2.76 |
| Resists | First : | 2.02 |
Second : | 2.37 |
| Pivot price | 1.61 |
|||
| Supports | First : | 1.48 |
Second : | 1.14 |
| MAs | MA(5) : | 1.78 |
MA(20) : | 1.52 |
| MA(100) : | 0.92 |
MA(250) : | 1.19 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 93.5  |
D(3) : | 92.4 |
| RSI | RSI(14): 75.8 |
|||
| 52-week | High : | 4.01 | Low : | 0.36 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ TNYA ] has closed above the upper band by 7.3%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 82.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.86 - 1.87 | 1.87 - 1.87 |
| Low: | 1.7 - 1.71 | 1.71 - 1.72 |
| Close: | 1.82 - 1.83 | 1.83 - 1.84 |
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
Thu, 02 Oct 2025
Tenaya Therapeutics CEO Faraz Ali to Speak at Upcoming Investor and Industry Conferences in October 2025 - Quiver Quantitative
Thu, 02 Oct 2025
Tenaya Therapeutics to Participate in Upcoming October Investor Conferences - GlobeNewswire
Thu, 02 Oct 2025
Oct 6 & Oct 21: Tenaya Therapeutics CEO Faraz Ali to Present at Investor Conferences — Webcast Archived 30 Days - Stock Titan
Tue, 02 Sep 2025
Heart Disease Biotech Tenaya Therapeutics Featured at Morgan Stanley Global Healthcare Conference 2025 - Stock Titan
Tue, 02 Sep 2025
Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference - GlobeNewswire
Mon, 18 Aug 2025
Tenaya Therapeutics’ Stocks Soar: Right Time to Buy? - StocksToTrade
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 163 (M) |
| Shares Float | 153 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 22.2 (%) |
| Shares Short | 15,050 (K) |
| Shares Short P.Month | 11,920 (K) |
| EPS | -0.94 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.61 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -45.2 % |
| Return on Equity (ttm) | -85.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.58 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -77 (M) |
| Levered Free Cash Flow | -43 (M) |
| PE Ratio | -2.14 |
| PEG Ratio | 0 |
| Price to Book value | 3.28 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.25 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|